165 related articles for article (PubMed ID: 33574967)
1. Prognostic Value of Soluble Suppression of Tumorigenicity 2 in Chronic Kidney Disease Patients: A Meta-Analysis.
Guo G; Huang A; Huang X; Xu T; Yao L
Dis Markers; 2021; 2021():8881393. PubMed ID: 33574967
[TBL] [Abstract][Full Text] [Related]
2. GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD.
Tuegel C; Katz R; Alam M; Bhat Z; Bellovich K; de Boer I; Brosius F; Gadegbeku C; Gipson D; Hawkins J; Himmelfarb J; Ju W; Kestenbaum B; Kretzler M; Robinson-Cohen C; Steigerwalt S; Bansal N
Am J Kidney Dis; 2018 Oct; 72(4):519-528. PubMed ID: 29866459
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of soluble ST2 and soluble LR11 on mortality and cardiovascular events in peritoneal dialysis patients.
Choi YB; Lee MJ; Park JT; Han SH; Kang SW; Yoo TH; Kim HJ
BMC Nephrol; 2020 Jun; 21(1):228. PubMed ID: 32539731
[TBL] [Abstract][Full Text] [Related]
4. Increased Plasma Concentrations of Soluble ST2 Independently Predict Mortality but not Cardiovascular Events in Stable Coronary Heart Disease Patients: 13-Year Follow-up of the KAROLA Study.
Pfetsch V; Sanin V; Jaensch A; Dallmeier D; Mons U; Brenner H; Koenig W; Rothenbacher D
Cardiovasc Drugs Ther; 2017 Apr; 31(2):167-177. PubMed ID: 28283847
[TBL] [Abstract][Full Text] [Related]
5. Soluble ST2 and Galectin-3 as Predictors of Chronic Kidney Disease Progression and Outcomes.
Kim AJ; Ro H; Kim H; Chang JH; Lee HH; Chung W; Jung JY
Am J Nephrol; 2021; 52(2):119-130. PubMed ID: 33725696
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure: A Meta-Analysis.
Aimo A; Vergaro G; Passino C; Ripoli A; Ky B; Miller WL; Bayes-Genis A; Anand I; Januzzi JL; Emdin M
JACC Heart Fail; 2017 Apr; 5(4):280-286. PubMed ID: 27816512
[TBL] [Abstract][Full Text] [Related]
7. Soluble ST2 is a biomarker for cardiovascular mortality related to abnormal glucose metabolism in high-risk subjects.
Cardellini M; Rizza S; Casagrande V; Cardolini I; Ballanti M; Davato F; Porzio O; Canale MP; Legramante JM; Mavilio M; Menghini R; Martelli E; Farcomeni A; Federici M
Acta Diabetol; 2019 Mar; 56(3):273-280. PubMed ID: 30259114
[TBL] [Abstract][Full Text] [Related]
8. The association between soluble suppression of tumorigenicity-2 and long-term prognosis in patients with coronary artery disease: A meta-analysis.
Liu N; Hang T; Gao X; Yang W; Kong W; Lou Q; Yang J
PLoS One; 2020; 15(9):e0238775. PubMed ID: 32886697
[TBL] [Abstract][Full Text] [Related]
9. Impacts of chronic kidney disease and diabetes on cardiovascular mortality in a general Japanese population: A 20-year follow-up of the NIPPON DATA90 study.
Hirata A; Okamura T; Sugiyama D; Kuwabara K; Kadota A; Fujiyoshi A; Miura K; Okuda N; Ohkubo T; Okayama A; Ueshima H;
Eur J Prev Cardiol; 2017 Mar; 24(5):505-513. PubMed ID: 27856810
[TBL] [Abstract][Full Text] [Related]
10. sST2 as a New Biomarker of Chronic Kidney Disease-Induced Cardiac Remodeling: Impact on Risk Prediction.
Plawecki M; Morena M; Kuster N; Chenine L; Leray-Moragues H; Jover B; Fesler P; Lotierzo M; Dupuy AM; Klouche K; Cristol JP
Mediators Inflamm; 2018; 2018():3952526. PubMed ID: 30402040
[TBL] [Abstract][Full Text] [Related]
11. Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure.
Aimo A; Vergaro G; Ripoli A; Bayes-Genis A; Pascual Figal DA; de Boer RA; Lassus J; Mebazaa A; Gayat E; Breidthardt T; Sabti Z; Mueller C; Brunner-La Rocca HP; Tang WH; Grodin JL; Zhang Y; Bettencourt P; Maisel AS; Passino C; Januzzi JL; Emdin M
JACC Heart Fail; 2017 Apr; 5(4):287-296. PubMed ID: 28189578
[TBL] [Abstract][Full Text] [Related]
12. Superior prognostic value of soluble suppression of tumorigenicity 2 for the short-term mortality of maintenance hemodialysis patients compared with NT-proBNP: a prospective cohort study.
Wang Z; Chen Z; Yu H; Ma X; Zhang C; Qu B; Zhang W; Chen X
Ren Fail; 2020 Nov; 42(1):523-530. PubMed ID: 32460670
[No Abstract] [Full Text] [Related]
13. Prognostic value of soluble suppression of tumorigenesis-2 (sST2) for cardiovascular events in coronary artery disease patients with and without diabetes mellitus.
Li M; Duan L; Cai Y; Hao B; Chen J; Li H; Liu H
Cardiovasc Diabetol; 2021 Feb; 20(1):49. PubMed ID: 33608010
[TBL] [Abstract][Full Text] [Related]
14. Serum Klotho, Cardiovascular Events, and Mortality in Nondiabetic Chronic Kidney Disease.
Yang K; Yang J; Bi X; Yu Z; Xiao T; Huang Y; Liu Y; Xiong J; Zhao J
Cardiorenal Med; 2020; 10(3):175-187. PubMed ID: 32294646
[TBL] [Abstract][Full Text] [Related]
15. Short-term and long-term prognostic value of circulating soluble suppression of tumorigenicity-2 concentration in acute coronary syndrome: a meta-analysis.
Gu L; Li J
Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31092701
[No Abstract] [Full Text] [Related]
16. Abnormal ankle-brachial index and risk of cardiovascular or all-cause mortality in patients with chronic kidney disease: a meta-analysis.
Chen HY; Wei F; Wang LH; Wang Z; Meng J; Yu HB; Zhang RN; Sun GJ; Jiang AL; Wang L
J Nephrol; 2017 Aug; 30(4):493-501. PubMed ID: 28197971
[TBL] [Abstract][Full Text] [Related]
17. Association of serum chloride level with mortality and cardiovascular events in chronic kidney disease: the CKD-ROUTE study.
Mandai S; Kanda E; Iimori S; Naito S; Noda Y; Kikuchi H; Akazawa M; Oi K; Toda T; Sohara E; Okado T; Sasaki S; Rai T; Uchida S
Clin Exp Nephrol; 2017 Feb; 21(1):104-111. PubMed ID: 27039905
[TBL] [Abstract][Full Text] [Related]
18. Prognostic role of soluble suppression of tumorigenicity-2 on cardiovascular mortality in outpatients with heart failure.
Gül İ; Yücel O; Zararsız A; Demirpençe Ö; Yücel H; Zorlu A; Yılmaz MB
Anatol J Cardiol; 2017 Sep; 18(3):200-205. PubMed ID: 28761021
[TBL] [Abstract][Full Text] [Related]
19. Cardiac and Stress Biomarkers and Chronic Kidney Disease Progression: The CRIC Study.
Bansal N; Zelnick L; Shlipak MG; Anderson A; Christenson R; Deo R; deFilippi C; Feldman H; Lash J; He J; Kusek J; Ky B; Seliger S; Soliman EZ; Go AS;
Clin Chem; 2019 Nov; 65(11):1448-1457. PubMed ID: 31578216
[TBL] [Abstract][Full Text] [Related]
20. Soluble ST2, a biomarker of fibrosis, is associated with multiple risk factors, chronic diseases and total mortality in the OPERA study.
Filali Y; Kesäniemi YA; Ukkola O
Scand J Clin Lab Invest; 2021 Jul; 81(4):324-331. PubMed ID: 33794701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
